



(43) International Publication Date
7 August 2014 (07.08.2014)

(10) International Publication Number
WO 2014/120784 A1

(51) International Patent Classification:

C07D 487/10 (2006.01) *A61P 25/00* (2006.01)
A61K 31/40 (2006.01)

(21) International Application Number:

PCT/US2014/013621

(22) International Filing Date:

29 January 2014 (29.01.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/757,920 29 January 2013 (29.01.2013) US

(71) Applicant: **NAUREX, INC.** [US/US]; 1801 Maple Avenue, Suite 4300, Evanston, IL 60201 (US).

(72) Inventors: **LOWE, John, A., III**; 28 Cove Side Lane, Stonington, CT 06378 (US). **KHAN, M., Amin**; 720 Oakton Street, #3a, Evanston, IL 60202 (US).

(74) Agents: **KAVANAUGH, Theresa, C.** et al.; Goodwin Procter LLP, Exchange Place, Boston, MA 02109 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

(57) Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.



WO 2014/120784 A1